• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Magnetic interactions and in vitro study of biocompatible hydrocaffeic acid-stabilized Fe–Pt clusters as MRI contrast agents
【24h】

Magnetic interactions and in vitro study of biocompatible hydrocaffeic acid-stabilized Fe–Pt clusters as MRI contrast agents

机译：生物相容性水合咖啡酸稳定的Fe–Pt团簇作为MRI造影剂的磁相互作用和体外研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A detailed magnetic study of separated Fe–Pt NPs and Fe–Pt clusters was performed to predict their optimal size and morphology for the maximum saturation magnetization, a factor that is known to influence the performance of a magnetic-resonance-imaging (MRI) contrast agent. Excellent stability and biocompatibility of the nanoparticle suspension was achieved using a novel coating based on hydrocaffeic acid (HCA), which was confirmed with a detailed Fourier-transform infrared spectroscopy (FTIR) study. An in vitro study on a human-bladder papillary urothelial neoplasm RT4 cell line confirmed that HCA-Fe–Pt nanoparticles showed no cytotoxicity, even at a very high concentration (550 μg Fe–Pt per mL), with no delayed cytotoxic effect being detected. This indicates that the HCA coating provides excellent biocompatibility of the nanoparticles, which is a prerequisite for the material to be used as a safe contrast agent for MRI. The cellular uptake and internalization mechanism were studied using ICP-MS and TEM analyses. Furthermore, it was shown that even a very low concentration of Fe–Pt nanoparticles (<10 μg mL ~(?1) ) in the cells is enough to decrease the T _(2) relaxation times by 70%. In terms of the MRI imaging, this means a large improvement in the contrast, even at a low nanoparticle concentration and an easier visualization of the tissues containing nanoparticles, proving that HCA-coated Fe–Pt nanoparticles have the potential to be used as an efficient and safe MRI contrast agent.
机译：对分离的Fe–Pt NP和Fe–Pt团簇进行了详细的磁性研究，以预测其最大饱和磁化强度的最佳大小和形态，已知该因素会影响磁共振成像（MRI）对比的性能代理商。使用基于咖啡因酸（HCA）的新型涂层，纳米颗粒悬浮液具有出色的稳定性和生物相容性，这一点已通过详细的傅里叶变换红外光谱（FTIR）研究得到证实。对人膀胱乳头状尿路上皮肿瘤RT4细胞系的体外研究证实，即使在非常高的浓度（550μgFe–Pt / mL）下，HCA-Fe–Pt纳米颗粒也没有细胞毒性，也没有发现延迟的细胞毒性作用。这表明HCA涂层提供了纳米颗粒的优异生物相容性，这是将该材料用作MRI的安全造影剂的前提。使用ICP-MS和TEM分析研究细胞的摄取和内在化机理。此外，研究表明，即使细胞中浓度非常低的Fe-Pt纳米颗粒（<10μgmL〜（？1））也足以使T _（2）弛豫时间减少70％。就MRI成像而言，这意味着即使在低纳米颗粒浓度下，对比度也有很大改善，并且可以更轻松地查看包含纳米颗粒的组织，从而证明HCA涂层的Fe–Pt纳米颗粒有可能被用作高效的和安全的MRI造影剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号